In our study, we tested the effect of the SGLT-2 inhibitor empagliflozin on metabolic parameters and insulin resistance using non-obese hHTG rats, a strain characterised by elevated concentrations of TAG; muscle and adipose tissue insulin resistance; hyperinsulinemia and impaired glucose tolerance [23,24,25]. Here, SLC5A2 is linked to hyperinsulinism.